Free Trial

Atea Pharmaceuticals Q2 2023 Earnings Report

Atea Pharmaceuticals logo
$3.16 +0.06 (+1.94%)
(As of 12/17/2024 ET)

Atea Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Atea Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atea Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Atea Pharmaceuticals Earnings Headlines

Vacuum up cash with these special trades?
Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.
See More Atea Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atea Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your email.

About Atea Pharmaceuticals

Atea Pharmaceuticals (NASDAQ:AVIR), a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

View Atea Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings